CLGN20241220P2.5
CLGN Dec 20 2024 2.50 Put (CLGN241220P00002500)
option OPRA

collplant is a regenerative medicine company focused on 3d bioprinting of tissues and organs, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. our products are based on our rhcollagen (recombinant human collagen) that is produced with collplant's proprietary plant based genetic engineering technology. our products address indications for diverse fields of organ and tissue repair, and are ushering in a new era in regenerative medicine. our flagship rhcollagen bioink product line is ideal for 3d bioprinting of tissues and organs, and our unique vergenix line of rhcollagen products includes a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote a rapid optimal healing of acute and chronic wounds. collplant is a public company listed on the tel aviv stock exchange and on nasdaq (clgn).